Targeting sphingosine-1-phosphate axis in obesity-promoted hepatocellular carcinoma

• Grant number: 14/15780-4
• Support type: Scholarships abroad - Research
• Effective date (Start): March 01, 2015
• Effective date (End): February 29, 2016
• Field of knowledge: Biological Sciences - Biochemistry - Molecular Biology
• Principal Investigator: Andréia Machado Leopoldino
• Grantee: Andréia Machado Leopoldino
• Host: Sarah Spiegel
• Home Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Local de pesquisa : Virginia Commonwealth University (VCU), United States

Abstract

This proposal will provide evidence that the SphK1/S1P/S1PR1 axis is one of the critical factors that bridge obesity, inflammation, and hepatocellular carcinoma (HCC)[1-5]. Surgical procedures such as liver resection and liver transplantation are the first-line treatments for HCC patients. However, the high incidence of tumor recurrence and metastasis after liver surgery remains a major problem [6, 7]. Therefore, development of novel therapies are need to eliminate tumor recurrence and metastasis after liver surgery. This proposal will pave the way for development of new cancer therapeutics targeting the SphK1/S1P/S1PR1 axis as a promising strategy for effective treatment of HCC. Targeting this axis that leads to NFkb -IL6-STAT3 amplification loop could also disrupt existing pre-metastatic niches and thus may prevent metastasis and recurrence that is a major problem in HCC. The strategies used for this study will be based on an animal model for obesity-promoted hepatocellular carcinoma development and progression using DEN-induced HCC (diethylnitrosamine) combined with diet-induced obesity ("high fat diet") in mice C57Bl/6 wild type and SphK1 knockout. In addition, signaling pathway inhibitors for S1PR1-SphK1-S1P will be used. Various methodologies will be applied to evaluate the physiological, cellular and molecular effects in each condition studied. (AU)